Alkem Laboratories has approved an investment of up to ₹75 crore to set up a new block within its existing manufacturing facility located in Baddi, Himachal Pradesh. The board of directors sanctioned this capital allocation on August 14, 2026, marking a specific deployment of funds towards capacity expansion at the company's northern manufacturing hub.

Investment details

The following table summarises the key details of the approved investment:

The approval reflects a formal commitment by Alkem Laboratories to deploy capital up to the sanctioned limit for infrastructure development. The company made the disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

No further operational or structural details regarding the timeline or specific product lines for the new block were disclosed alongside this announcement.

Alkem Laboratories Limited has appointed Rajpal Singh Rana as Senior Vice President - Marketing & Sales for the Acute Cluster, effective August 3, 2026. The company disclosed the senior management change to the stock exchanges pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This leadership addition aims to strengthen the company’s commercial operations in its acute care segment.

The appointment was communicated to the Bombay Stock Exchange and the National Stock Exchange of India Limited on August 3, 2026. Divya Mewani, Vice President – Legal & Deputy Company Secretary at Alkem Laboratories, signed the disclosure letter. The company stated that the information is also available on its official website.

Appointment Details

Rana’s contract term is defined as continuing for as long as he remains in the employment of the company. The filing did not disclose any specific fixed tenure or performance-linked exit clauses. There are no disclosed relationships between Rana and the company’s directors.

Professional Profile

Rana is an experienced pharmaceutical professional with over 30 years of experience in marketing and sales. Before joining Alkem Laboratories, he worked with various other pharmaceutical companies. He holds an MBA in Marketing from Sikkim Manipal University and a B.Sc. in Physics, Chemistry & Mathematics from Delhi University.

Regulatory Context

The disclosure was made under Regulation 30(2) of the SEBI LODR Regulations, read with Schedule III, Part A. The company also referenced the SEBI Master Circular bearing number HO/49/14/14(7)2025-CFDPOD2/1/3762/2026 dated January 30, 2026, regarding the format and content of such disclosures. The appointment does not involve any change in the board composition or promoter holding.